CRISPR/Cas9 tech agreement for corneal blindness cell therapies  

CRISPR-Cas9

ERS Genomics, a CRISPR/Cas9 licensing company, and StemSight, a biotechnology company developing stem cell based therapies for corneal blindness, have entered a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio. 

StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for unmet medical needs in corneal blindness. Led by a team of scientists in the field of stem cells and tissue engineering for eye applications, StemSight originated as a spin-out from pluripotent stem cell expert Professor Heli Skottman’s laboratory at Tampere University.  

Dr Laura Koivusalo, CEO and Co-founder of StemSight, said: “This partnership with ERS Genomics is a significant leap forward for StemSight. By harnessing the remarkable capabilities of CRISPR/Cas9 we will be able to address major challenges of the current allogeneic cell therapies, ultimately bringing us closer to life-changing therapies for patients with currently incurable blindness.” 

Eric Rhodes, CEO of ERS Genomics, commented: “We are pleased to add StemSight to our family of licensees. This collaboration underscores the growing prominence of Finland, and the Nordics, in the global biotechnology and life science sector. StemSight’s use of CRISPR/Cas9 technology to develop regenerative therapies that will change the lives of patients suffering from limbal stem cell deficiency is truly pioneering.” 

ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier. The company provides licensing for companies interested in pursuing CRISPR/Cas9’s use in their commercial programmes. With 89 patents held in over 90 countries, ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide. 

Further licensing agreements reported by DDW include: NUVISAN ICB, Setsuro Tech, G+FLAS Life Sciences, ZeClinics, and more. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free